Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIUPRES-250 vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension (adjunctive therapy),Edema associated with congestive heart failure, cirrhosis, or renal disease (hydrochlorothiazide component)
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Hydroflumethiazide: 6-18 hours (prolonged in renal impairment). Reserpine: 50-100 hours (biphasic; terminal phase).
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Hydrochlorothiazide is not metabolized; excreted unchanged by the kidneys. Reserpine undergoes extensive hepatic metabolism via CYP3A4 oxidation.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Renal: approximately 50% of hydroflumethiazide is excreted unchanged in urine; reserpine is extensively metabolized with <1% excreted unchanged. Fecal: minimal.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Hydroflumethiazide: 75-80% bound to plasma proteins. Reserpine: approximately 95% bound (primarily to albumin).
~20% bound to albumin; minimal binding to other plasma proteins.
Hydroflumethiazide: 3-8 L/kg (extensive distribution). Reserpine: 9-12 L/kg (highly lipid-soluble, crosses blood-brain barrier).
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Oral: hydroflumethiazide ~70% (variability); reserpine ~40% (first-pass metabolism).
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
Contraindicated if GFR <30 m L/min. For GFR 30-60 m L/min: use 1 tablet every other day; avoid if GFR <30 m L/min.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or increase dosing interval. Child-Pugh C: contraindicated.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended for pediatric use due to reserpine component; safety and efficacy not established.
Not recommended; inadequate safety data.
Initiate at 1 tablet every other day; monitor for electrolyte disturbances, orthostatic hypotension, and central nervous system effects.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
No FDA black box warning identified. Reserpine use may be associated with increased risk of breast cancer (historical concern, not confirmed), but no official boxed warning.
None
Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Hyperuricemia and gout,Increased blood urea nitrogen (BUN) and creatinine,Photosensitivity with thiazides,Mental depression with reserpine (history of depression, suicidal ideation),Bradycardia, hypotension, and sedation with reserpine,Exacerbation of peptic ulcer disease (reserpine increases gastric acid secretion),Possible withdrawal syndromes (severe hypertension, tachycardia) upon abrupt discontinuation
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Hypersensitivity to hydrochlorothiazide, reserpine, or sulfonamide-derived drugs,Anuria or severe renal impairment,Active peptic ulcer disease or ulcerative colitis,History of major depression or electroconvulsive therapy,Concurrent use with MAO inhibitors (MAOIs) or within 14 days of discontinuation,Pheochromocytoma (reserpine may cause paradoxical hypertension),Electroconvulsive therapy (relative contraindication due to risk of prolonged seizure or apnea)
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid high-sodium foods to enhance antihypertensive effect. Alcohol may increase orthostatic hypotension. Grapefruit juice may alter reserpine metabolism (caution). Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) if also taking MAOIs, but not typically required with reserpine alone. Maintain adequate potassium intake (bananas, oranges) due to hydrochlorothiazide-induced potassium loss.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: Use cautiously due to potential fetal bradycardia from the reserpine component; second and third trimesters: Risk of fetal hypotension, bradycardia, and hypothermia; reserpine crosses placenta and may cause neonatal respiratory depression and nasal congestion.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Excreted in breast milk; M/P ratio not established; reserpine may cause infant drowsiness, bradycardia, and GI upset; hydrochlorothiazide may decrease milk supply; generally avoid breastfeeding or use with caution.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
Increased plasma volume and renal clearance in pregnancy may require dose adjustment for hydrochlorothiazide; reserpine pharmacokinetics not well studied; use lowest effective dose; gradual dose reduction recommended near term to avoid neonatal effects.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
DIUPRES-250 (hydrochlorothiazide 25 mg / reserpine 0.125 mg) is a fixed-dose combination antihypertensive. Reserpine depletes catecholamines, causing orthostatic hypotension and nasal congestion. Hydrochlorothiazide may cause hypokalemia, hyperglycemia, and photosensitivity. Avoid in patients with history of depression (reserpine). Monitor serum potassium, glucose, and uric acid. Onset of full effect may take weeks due to reserpine.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take this medication exactly as prescribed, at the same time each day.,Stand up slowly to avoid dizziness or fainting.,Expect nasal congestion which may improve over time.,Use sunscreen and protective clothing to avoid sunburn.,Do not stop abruptly without consulting your doctor (risk of severe hypertension).,Report any mood changes, breast tenderness, or abdominal pain to your doctor.,Avoid driving or operating machinery until you know how this medicine affects you.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIUPRES-250 vs ALDORIL D50, answered by our medical review team.
DIUPRES-250 is a Antihypertensive Combination that works by Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIUPRES-250 and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIUPRES-250 is: 1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DIUPRES-250 and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DIUPRES-250 is classified as Category C. First trimester: Use cautiously due to potential fetal bradycardia from the reserpine component; second and third trimesters: Risk of fetal hypotension, bradycardia, and hypothermi. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.